Leigh Ellis

7.8k total citations · 1 hit paper
55 papers, 2.9k citations indexed

About

Leigh Ellis is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Leigh Ellis has authored 55 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 28 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Leigh Ellis's work include Prostate Cancer Treatment and Research (24 papers), Histone Deacetylase Inhibitors Research (14 papers) and Ubiquitin and proteasome pathways (10 papers). Leigh Ellis is often cited by papers focused on Prostate Cancer Treatment and Research (24 papers), Histone Deacetylase Inhibitors Research (14 papers) and Ubiquitin and proteasome pathways (10 papers). Leigh Ellis collaborates with scholars based in United States, Australia and Italy. Leigh Ellis's co-authors include Роберто Пили, Ricky W. Johnstone, Peter Atadja, Hans J. Hammers, Sheng‐Yu Ku, Swathi Ramakrishnan, Spencer R. Rosario, David W. Goodrich, Mukund Seshadri and Eduardo Cortes Gomez and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Leigh Ellis

55 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

2017 680 citations Sheng‐Yu Ku, Spencer R. Rosario et al. Science profile →

Peers

Leigh Ellis

PRM

ONCOL

IMMUN

James V. Alvarez United States

Jinyun Liu United States

Mahmoud Toulany Germany

Danan Li United States

Haili Qian China

Emma Dean United Kingdom

Matthias Bache Germany

David A. Proia United States

Paolo Ceppi Italy

Antonella Papa United States

James V. Alvarez United States

Leigh Ellis

1.1k ×0.5

636 ×0.7

PRM

1.1k ×1.3

ONCOL

482 ×0.9

293 ×0.9

IMMUN

Citations per year, relative to Leigh Ellis Leigh Ellis (= 1×) peers James V. Alvarez

Countries citing papers authored by Leigh Ellis

Since Specialization

Citations

This map shows the geographic impact of Leigh Ellis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leigh Ellis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leigh Ellis more than expected).

Fields of papers citing papers by Leigh Ellis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leigh Ellis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leigh Ellis. The network helps show where Leigh Ellis may publish in the future.

Co-authorship network of co-authors of Leigh Ellis

This figure shows the co-authorship network connecting the top 25 collaborators of Leigh Ellis. A scholar is included among the top collaborators of Leigh Ellis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leigh Ellis. Leigh Ellis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alaiwi, Sarah Abou, Marcos A. Fonseca, Deborah L. Burkhart, et al.. (2024). MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer. Cancer Research Communications. 4(9). 2295–2307. 5 indexed citations

Gong, Jun, Michael R. Freeman, Hyung L. Kim, et al.. (2023). Genetic and biological drivers of prostate cancer disparities in Black men. Nature Reviews Urology. 21(5). 274–289. 16 indexed citations

Yan, Yiwu, Bo Zhou, Qian Chen, et al.. (2022). Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nature Communications. 13(1). 669–669. 28 indexed citations

Adashek, Jacob J., Joshua J. Breunig, Edwin M. Posadas, et al.. (2022). First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?. Drugs. 82(4). 439–453. 4 indexed citations

Héninger, Erika, David Kosoff, Nan Sethakorn, et al.. (2021). Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling. Medical Oncology. 38(11). 135–135. 15 indexed citations

Wang, Yu, Mackenzie K. Herroon, Steven P. Zielske, et al.. (2021). Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasis. Journal of bone oncology. 30. 100386–100386. 1 indexed citations

Burkhart, Deborah L., Katherine L. Morel, Kristine M. Wadosky, et al.. (2020). Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prevention Research. 13(12). 979–988. 4 indexed citations

Miyahira, Andrea K., Adam Sharp, Leigh Ellis, et al.. (2019). Prostate cancer research: The next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting. The Prostate. 80(2). 113–132. 30 indexed citations

Burkhart, Deborah L., et al.. (2019). The Role of RB in Prostate Cancer Progression. Advances in experimental medicine and biology. 1210. 301–318. 16 indexed citations

10.

Ku, Sheng‐Yu, Spencer R. Rosario, Yanqing Wang, et al.. (2017). Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 355(6320). 78–83. 680 indexed citations breakdown →

11.

Olson, Brian M., Justin J. Jeffery, Leigh Ellis, et al.. (2017). Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. Cancer Immunology Research. 5(12). 1074–1085. 28 indexed citations

12.

Miyahira, Andrea K., Heather H. Cheng, Wassim Abida, et al.. (2017). Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey‐Holden Prostate Cancer Academy Meeting. The Prostate. 77(15). 1478–1488. 10 indexed citations

13.

Lasorsa, Elena, et al.. (2015). Mitochondrial protection impairs BET bromodomain inhibitor-mediated cell death and provides rationale for combination therapeutic strategies. Cell Death and Disease. 6(12). e2014–e2014. 18 indexed citations

14.

Shen, Li, Anette Sundstedt, Michael J. Ciesielski, et al.. (2014). Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models. Cancer Immunology Research. 3(2). 136–148. 74 indexed citations

15.

Ku, Sheng‐Yu, Elena Lasorsa, Remi Adelaiye‐Ogala, et al.. (2014). Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer. PLoS ONE. 9(7). e103680–e103680. 11 indexed citations

16.

Ellis, Leigh, Sheng‐Yu Ku, Swathi Ramakrishnan, et al.. (2013). Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. Oncotarget. 4(12). 2225–2236. 57 indexed citations

17.

Minelli, Rosalba, Roberta Cavalli, Leigh Ellis, et al.. (2012). Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European Journal of Pharmaceutical Sciences. 47(4). 686–694. 68 indexed citations

18.

Ellis, Leigh, et al.. (2011). Development of a castrate resistant transplant tumor model of prostate cancer. The Prostate. 72(6). 587–591. 17 indexed citations

19.

Ellis, Leigh, Swathi Ramakrishnan, Remi Adelaiye‐Ogala, et al.. (2011). Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression. PLoS ONE. 6(11). e27178–e27178. 17 indexed citations

20.

Ellis, Leigh, Yan Pan, Gordon K. Smyth, et al.. (2008). Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma. Clinical Cancer Research. 14(14). 4500–4510. 244 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact